{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:03:42Z","timestamp":1788188622166,"version":"build-2803163510"},"reference-count":21,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: MB09 is a denosumab biosimilar to the reference products (RPs) Xgeva and Prolia. A population pharmacokinetic (popPK) meta-analysis was conducted to characterize the denosumab PK profile and to support MB09 biosimilarity. Methods: Pooled denosumab PK data from one phase I study [255 healthy adult men receiving a single 35 mg subcutaneous (SC) dose] and one phase III study (555 postmenopausal women with osteoporosis receiving two 60 mg SC doses, one every six months) were used. A one-compartment model with first-order absorption and elimination and parallel non-linear saturable clearance was used. Body weight was included on clearance as a structural covariate and treatment was tested as a covariate on all PK parameters. PK biosimilarity was assessed at 35 mg dose. Results: For a 70 kg subject, the apparent clearance and central volume of distribution for denosumab were 0.123 L\/day [95% confidence interval (CI): 0.114, 0.132] and 9.33 L (95% CI: 9.11, 9.55), respectively. The Michaelis constant was 0.124 ng\/mL and the maximum rate for the non-linear clearance was 0.139 ng\/day. Model-based bioequivalence criteria were met for RP Xgeva, European and US-sourced, versus MB09 for a dose of 60 mg SC. The mean area under the plasma concentration curve (AUC) resultant from the simulation of MB09 120 mg SC was similar to the published mean AUC observed for Xgeva 120 mg SC every four weeks. Conclusions: This analysis provides a valuable assessment of denosumab PK characteristics and elucidates in more detail how the MB09 PK profile compares to the denosumab RPs, supporting the totality of evidence on MB09 biosimilarity.<\/jats:p>","DOI":"10.3390\/pharmaceutics17091146","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:27:44Z","timestamp":1756733264000},"page":"1146","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population PK Modeling of Denosumab Biosimilar MB09 and Reference Denosumab to Establish PK Similarity"],"prefix":"10.3390","volume":"17","author":[{"given":"Sara","family":"S\u00e1nchez-Vidaurre","sequence":"first","affiliation":[{"name":"Medical Department, mAbxience Research S.L., 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Paravisini","sequence":"additional","affiliation":[{"name":"Medical Department, mAbxience Research S.L., 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-4167","authenticated-orcid":false,"given":"Javier","family":"Queiruga-Parada","sequence":"additional","affiliation":[{"name":"Medical Department, mAbxience Research S.L., 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"ref_1","unstructured":"Prolia-PI (2025, May 23). Prolia-Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125320Orig1s221lbl.pdf."},{"key":"ref_2","unstructured":"Xgeva-PI (2025, May 23). Xgeva-Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125320s203lbl.pdf.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: Mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1111\/cts.70013","article-title":"MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects","volume":"17","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_5","unstructured":"Prolia-SmPC (2025, May 23). Prolia-Summary of Products Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf."},{"key":"ref_6","unstructured":"EMA\u2014NAMs (2025, August 25). Regulatory Acceptance of New Approach Methodologies (NAMs) to Reduce Animal Use Testing. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/ethical-use-animals-medicine-testing\/regulatory-acceptance-new-approach-methodologies-nams-reduce-animal-use-testing#main-content."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","article-title":"Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours","volume":"51","author":"Gibiansky","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/bdd.770","article-title":"Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women","volume":"32","author":"Marathe","year":"2011","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1359\/jbmr.2005.20.12.2274","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004","volume":"20","author":"Bekker","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/psp4.12404","article-title":"NONMEM Tutorial Part I: Description of Commands and Options, with Simple Examples of Population Analysis","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: Problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11530560-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development","volume":"24","author":"Mould","year":"2010","journal-title":"BioDrugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11598930-000000000-00000","article-title":"The relationship between drug clearance and body size: Systematic review and meta-analysis of the literature published from 2000 to 2007","volume":"51","author":"McLeay","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117371","DOI":"10.1016\/j.bone.2024.117371","article-title":"SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial","volume":"192","author":"Chung","year":"2025","journal-title":"Bone"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40259-023-00579-5","article-title":"Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial","volume":"37","author":"Li","year":"2023","journal-title":"BioDrugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","article-title":"Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: The ROSALIA study","volume":"39","author":"Jeka","year":"2024","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chen, Q., Hu, C., Liu, Y., Song, R., Zhu, W., Zhao, H., Nino, A., Zhang, F., and Liu, Y. (2018). Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197984"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12355","article-title":"The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: A systematic review","volume":"78","author":"Sohn","year":"2014","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1146\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:37:09Z","timestamp":1760035029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["pharmaceutics17091146"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17091146","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}